Summary by Moomoo AI
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a stock transaction involving the sale of 50,000 common shares on January 29, 2024. The shares were sold at prices ranging from $60.5031 to $61.0998, resulting in a total market value of $3,025,572.69. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 187,377 common shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.